Because the prevalence of KRAS mutations in breast cancer is very low, yet the RAS pathway signature is coherently expressed and predicts MEK inhibitor sensitivity and AKT inhibitor resistance in breast cancer cell lines, the RAS pathway signature may have the most immediate value for clinical development in breast cancer. Here, KRAS is linked to breast carcinoma.